New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
10:32 EDTIRE, MFC, SIG, MON, CLMT, SHPGHigh options volume: SHPG MON MFC CLMT SIG IRE
News For SHPG;MON;MFC;CLMT;SIG;IRE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
07:19 EDTSHPGShire says David Kappler to step down as deputy chairman
Subscribe for More Information
06:28 EDTSHPGShire upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information
February 9, 2016
16:14 EDTSHPGShire initiated with a Neutral at Guggenheim
14:04 EDTMONSEC reaches $80M settlement with Monsanto over accounting violations
Subscribe for More Information
12:04 EDTMONUSDA raises corn supply forecast by 35M bushels
In its monthly World Agricultural Supply and Demand Estimates report, the USDA raised its corn ending stocks estimate for 2015/16 by 35M bushels. The projected range for the corn season-average farm price is narrowed 5 cents on both ends to $3.35 to $3.85 per bushel. Publicly traded companies in the Agriculture and Fertilizer spaces include Agrium (AGU), Andersons (ANDE), Archer Daniels (ADM), Bunge (BG), CF Industries (CF), Compass Minerals (CMP), DuPont (DD), Intrepid Potash (IPI), Monsanto (MON), Mosaic (MOS), Potash (POT) and Syngenta (SYT).
09:56 EDTSHPGIntercept higher following report of vague takeover chatter
Shares of Intercept Pharmaceuticals (ICPT) are moving after United Kingdom blog Proactive Investors discussed "reheated rumours" of a takeover. "Vague talk" has Intercept teaming up with CenterView Partners to advise on a sale, the blog states. It mentions AstraZeneca (AZN) as a possible suitor now that Shire (SHPG) has reached an agreement to acquire Baxalta (BXLT). Shares of Intercept, which is developing treatments for chronic liver diseases, are up 4% to $97.39 in early trading.
February 4, 2016
16:00 EDTSHPGShire's NDA for lifitegrast for dry eye resubmssion acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the resubmission of the New Drug Application for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter received from the FDA on October 16, 2015 that requested an additional clinical study and more information related to product quality. The FDA determined that the submission is a complete response and has assigned a 6-month review period for the NDA and a Prescription Drug User Fee Act goal date of July 22.
February 3, 2016
08:07 EDTSHPGMedgenics names Brian Piper to succeed John Leaman as CFO
Subscribe for More Information
08:06 EDTMONMonsanto announces commercial launch plans for Roundup Ready 2 Xtend soybeans
Subscribe for More Information
February 2, 2016
09:46 EDTSHPGIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
January 28, 2016
10:05 EDTSHPGHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use